Genetic information firm Invitae has partnered with genomic profiling company KEW to develop new comprehensive genomic profiling solutions so it can sequence tumour DNA on its next-generation sequencing (NGS) platform.

KEW’s new capabilities for somatic mutation detection will be integrated with Invitae’s diagnostic genetic testing panels, which were developed for hereditary cancers to enable better cancer care, from diagnosis until treatment.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Invitae’s germline testing analyses inherited genetic changes that enhance the risk of certain cancers, while KEW’s somatic testing evaluates acquired DNA alterations that can drive a tumour’s growth.

“KEW’s new capabilities for somatic mutation detection will be integrated with Invitae’s diagnostic genetic testing panels, which were developed for hereditary cancers to enable better cancer care.”

Invitae CEO Sean George said: “Broadening our ability to capture genetic information on both tumour biology and a patient’s inherited risk of disease while maintaining our commitment to lowering cost enhances Invitae’s ability to expand the market and enable affordable, high-quality precision care for more patients.”

KEW’s CancerPlex sequencing assay helps in detecting somatic mutations in 435 genes and allows assessment of tumour mutational burden and microsatellite instability to identify potential responders to immune checkpoint inhibitors.

Invitae will fund both the new development project and the integration of KEW’s technology into its platform and workflow.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As part of the deal, the company will have access to KEW’s bioinformatics software and the CancerPlex sequencing assay.

KEW president and CEO Jerry Williamson said: “State-of-the-art bioinformatics has enabled Invitae to build out a uniquely scalable offering well suited to rapid integration with our proprietary algorithms for optimal and accurate genomic variant detection and curated knowledge base.

“We believe aligning these capabilities on a single platform will provide the basis for making molecular characterisation the standard of care.”